Is Oramed Pharmaceuticals Inc. (ORMP) a Buy, Sell, or Hold?
NASDAQ : ORMP
Oramed Pharmaceuticals Inc.
$4.25 USD
$0.05 (1.19%)
- Volume
- 159.36K
- Average Volume
- 247.48K
- Market Capitalization
- $173.94M
- P/E Ratio
- 1.00
- Dividend Yield
- 5.88%
- Price Target
- Year High
- $5.19
- Year Low
- $1.98
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.05
- Current Ratio
- $4.98
Company Overview
NASDAQ
Nadav Kidron
Biotechnology
Healthcare
ORMP
13
US
USD
Liquidity Metrics
0.00
4.98
4.98
1.42
0.05
Sales & Valuation
$2M
0.00
0.55
-32.37
-0.13
Profitability
$1.5
$64.05M
0.00%
0.00%
82.73%
62.71%
P/E Metrics
1.00
0.00
0.00
Analyst Price Target & Rating
4/5
8 Analysts
%
Financial Health Scores
3.30
3/9
$42.68M
$316.24M
$41.44M
$65.59M
Key Metrics (TTM)
$157.38M
0.00
2.40
4.98
82.73%
-3.46%
115.04%
-3.13%
$29.00
0 days
Company Executives
| Name | Title |
|---|---|
| Joshua Hexter | Chief Operating & Business Officer |
| Miriam Kidron | Chief Scientific Officer & Director |
| Nadav Kidron | President, Chief Executive Officer & Executive Chairman |
| Avraham Gabay | Chief Financial Officer, Treasurer & Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Stock
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officiall ... y changing its name to Oramed Pharmaceuticals Inc. in April 2006.
2026-06-25 12:00:00
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation
2026-06-25 11:35:00
Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million) Scilex (NASDAQ: SCLX) Loan Substantially Repaid Total Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026) Oramed to Join the Russell 2000 and Russell 3000 Indexes this week NEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repayment of its Scilex loan, and a strengthened balance sheet of approximately $270 million in total cash and assets, as of March 31, 2026 (unaudited).
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
2026-06-17 08:55:00
NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index at the conclusion of the 2026 Russell indexes semi-annual reconstitution. The 2026 Russell 2000 and Russell 3000 reconstitution becomes final after the close of US markets on Friday, June 26, and becomes effective for trading at the market open on Monday, June 29, according to a preliminary list of additions posted by FTSE Russell on May 22, 2026.
2026-05-22 15:31:30
Oramed Pharmaceuticals is downgraded from 'Strong Buy' to 'Hold' due to the failed phase 3 trial for ORMD-0801 in Type 2 Diabetes. ORMP pivots to target a subset of T2D patients and transfers its POD Technology to Lifeward, securing a 49.9% stake and potential revenue streams for ReWalk. Strategic investments in biotech and real estate diversify risk, but cash burn and limited liquidity raise near-term funding concerns.
Frequently Asked Questions
-
What is the current Oramed Pharmaceuticals Inc. (ORMP) stock price?
-
Oramed Pharmaceuticals Inc.(NASDAQ:ORMP) stock price is $4.25 in the last trading session. During the trading session, ORMP stock reached the peak price of $5.19 while $1.98 was the lowest point it dropped to. The percentage change in ORMP stock occurred in the recent session was 1.19% while the dollar amount for the price change in ORMP stock was $0.05.
-
ORMP's industry and sector of operation?
-
The NASDAQ listed ORMP is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ORMP?
-
Joshua Hexter | Chief Operating & Business Officer
Miriam Kidron | Chief Scientific Officer & Director
Nadav Kidron | President, Chief Executive Officer & Executive Chairman
Avraham Gabay | Chief Financial Officer, Treasurer & Secretary
| -
How many employees does ORMP have?
-
Number of ORMP employees currently stands at 13. ORMP operates from 1185 Avenue of the Americas, New York City, NY 10036, US.
-
Link for ORMP official website?
-
Official Website of ORMP is: https://www.oramed.com
-
How do I contact ORMP?
-
ORMP could be contacted at phone #844 967 2633 and can also be accessed through its website. ORMP operates from 1185 Avenue of the Americas, New York City, NY 10036, US.
-
How many shares of ORMP are traded daily?
-
The average number of ORMP shares traded daily for last 3 months was 247.48K.
-
What is the market cap of ORMP currently?
-
The market value of ORMP currently stands at $173.94M with its latest stock price at $4.25